Your browser doesn't support javascript.
loading
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial.
Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco.
Afiliação
  • Rosellini M; Medical Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Tassinari E; Medical Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Marchetti A; Medical Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Mollica V; Medical Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Massari F; Medical Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. Electronic address: francesco.massari@aosp.bo.it.
Eur Urol ; 85(1): 97-98, 2024 01.
Article em En | MEDLINE | ID: mdl-37777426

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Anilidas Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Eur Urol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Anilidas Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Eur Urol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália